An update from Genor Biopharma Holdings Limited ( ) is now available. Edding Genor Group Holdings Limited has received approval from China’s National Medical Products Administra ...

(9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study ...

Akeso announces first patient dosed in phase III perioperative study of cadonilimab in colon cancer: Hong Kong Monday, October 12, 2026, 16:00 Hrs [IST] Akeso, Inc., a leading bio ...

(9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study ...

Out of 2,995 new cancer cases recorded in Sarawak in 2025, breast cancer made up 476 new cases, along with 471 cases of colorectal cancer—showing that both ...

On October 10, Akeso announced that the first patient had been dosed in COMPASSION-40, a Phase III study of cadonilimab as a ...

"The last thing you want to do is ignore a change... and then realize it is from an advanced cancer that could have been ...

Phase III trial of cadonilimab begins in perioperative colon cancer, testing dual PD-1/CTLA-4 blockade in MSI-H/dMMR patients ...

The FDA approves Roche’s Tecentriq with chemotherapy for stage III dMMR colon cancer after a trial showed a 50% reduction in ...

Akeso, Inc. announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, as ...

The FDA has approved atezolizumab with chemotherapy after surgery for stage III colon cancer with deficient mismatch repair, ...

A short course of immunotherapy before surgery may offer remarkably durable protection for some patients with stage two or three bowel cancer. In the NEOPRISM-CRC trial, 32 patients with a specific ...